CD26. Human T cell lymphotropic virus serology was negative. The total lymphocyte count was 2610 cells/mm 3 (normal range, 900-3400 cells/mm 3 ) and lactate dehydrogenase was 333 U/L (normal range, 135-225 U/L). General laboratory tests showed no significant abnormalities.
Imaging studies showed axillary lymph node enlargement up to 3 cm bilaterally, without other significant findings, but a biopsy specimen was not obtained because the patient was lost to follow-up.
A diagnosis of double-positive CD4 and CD8 SS was made.
We evaluated the production of activation/inhibition molecules (CD69 and PD-1) and effector molecules (interferon gamma and CD107a), on TCD4 1 CD8 1 , TCD4 1 CD8 e , and TCD4 e CD8 1 cells unstimulated and after stimulation with phorbol myristate acetate (Fig 4, B and Table I ). Expression of CD69 and PD-1 were similar between the groups, but CD4 1 CD8 1 T cells were less responsive to the production of interferon gamma. Also, expression of CD107a, an indicator of cytotoxicity, were 5 times lower in CD4 1 CD8 1 cells than in CD4 1 CD8 e cells.
DISCUSSION
SS is a cutaneous T-cell lymphoma with peripheral blood involvement by malignant cells (S ezary cells). Clinically, it presents with erythroderma and varying degrees of skin infiltration, nonscarring diffuse alopecia, palmoplantar keratoderma, nail involvement, lymphadenopathy, intense pruritus, and weight loss. 1 One to 10% of erythroderma, or exfoliative dermatitis, is caused by SS. 2 Diagnostic criteria include T-cell receptor (TCR) gene rearrangement analysis with a monoclonal population of T-lymphocytes in the blood and matching clone infiltrating the skin. S ezary cell count in peripheral blood smear should be $ 1000 cells/L or should have 1 of 2 immunophenotypic criteria, which are a CD4/CD8 ratio $ 10 or increase in CD4 cells with abnormal phenotype (CD4 1 CD7 e $ 40% or CD4 1 CD26 e $ 30%). 3 Formerly thought to be a leukemic variant of mycosis fungoides, there are now different opinions if SS may be considered another disease, with different immunophenotypes of malignant cells and different genetic mutations. 4, 5 Occasionally, with the improvement of erythroderma, classic lesions of mycosis fungoides become evident, contrary to the hypothesis that they may be different diseases.
Classically, SS is a CD4 1 T-cell neoplasm, with the lymphocytes expressing the pan-T CD3 cell marker, CD4 phenotype, CCR4 (skin homing adressin), CCR7, and L-selectin (lymph node homing adressins), the immunophenotype of central memory T-lymphocytes. By contrast, mycosis fungoides malignant cells express CCR4 and cutaneous lymphocyte antigen but lack lymph node homing adressins. 4 There are few reports of CD8 1 cutaneous T-cell lymphomas, with different clinical presentations and outcomes. Primary cutaneous aggressive epidermotropic CD8 1 cytotoxic T-cell lymphoma is a provisional entity with aggressive clinical course. 6 There are few reports of other cutaneous T-cell lymphomas expressing the CD8 phenotype, such as pagetoid reticulosis, mycosis fungoides, lymphomatoid papulosis, cutaneous anaplastic large cell lymphoma, and SS. 6, 7 Double-positive CD4 and CD8 lymphoproliferative diseases are extremely rare, with anecdotal reports in the literature. Most cases had adult T-cell leukemia/lymphoma and large granular lymphocytic leukemia. There was 1 report of CD4 1 CD8 1 mycosis fungoides 8 and 1 report of double-positive SS. 9 A previous study from our group showed a deficient immune response in patients with SS. 10 The data suggest that double-positive CD4 1 CD8 1 neoplastic T-cells shows a lower cytotoxic potential compared to CD4 1 CD8 e cells.
CONCLUSIONS
We report an unusual case of double-positive SS in an erythrodermic patient. We emphasize the need for comprehensive and detailed clinical and laboratory investigation of every patient who presents with erythroderma. Careful evaluation should be made to detect any infectious or tumoral progression in Sixty-eight percent of CD4 1 and CD8 1 malignant cells. B, CD107a and interferon gamma production after stimulation with phorbol miristate acetate in TCD4 1 CD8 1 neoplastic cells, TCD4 1 CD8 e , and TCD4 e CD8 1 cells. Peripheral blood mononuclear cells were cultured with phorbol miristate acetate (50 ng/mL) and ionomycin (1 g/mL) for 20 hours. T cells were assessed for interferon production and activation markers expression by flow cytometry. VOLUME 3, NUMBER 6 patients with double-positive CD4 and CD8 SS because of their immunosuppressive state. 
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